Table 1.
Baseline patient and tumour characteristics by centre
| All (n = 3180) | EORTC centres | ||||
|---|---|---|---|---|---|
| Centre 1 (n = 398) | Centre 2 (n = 1082) | Centre 3 (n = 953) | Centre 4 (n = 747) | ||
| Age (years)* | 55 (44–67) | 51 (40–62) | 63 (49–71) | 51 (42–62) | 55 (44–65)† |
| Sex | |||||
| F | 1668 (52·5) | 211 (53·0) | 478 (44·2) | 589 (61·8) | 390 (52·2) |
| M | 1510 (47·5) | 187 (47·0) | 604 (55·8) | 364 (38·2) | 355 (47·5) |
| Missing | 2 (0·1) | 0 (0) | 0 (0) | 0 (0) | 2 (0·3) |
| Anatomical site | |||||
| Arm | 556 (17·5) | 74 (18·6) | 187 (17·3) | 180 (18·9) | 115 (15·4) |
| Leg | 996 (31·3) | 146 (36·7) | 255 (23·6) | 369 (38·7) | 226 (30·3) |
| Trunk | 1360 (42·8) | 162 (40·7) | 517 (47·8) | 390 (40·9) | 291 (39·0) |
| Head and neck | 259 (8·1) | 16 (4·0) | 123 (11·4) | 13 (1·4) | 107 (14·3) |
| Missing | 9 (0·3) | 0 (0) | 0 (0) | 1 (0·1) | 8 (1·1) |
| Histological type | |||||
| SSM | 1739 (54·7) | 204 (51·3) | 762 (70·4) | 307 (32·2) | 466 (62·4) |
| NM | 885 (27·8) | 134 (33·7) | 204 (18·9) | 353 (37·0) | 194 (26·0) |
| ALM | 93 (2·9) | 10 (2·5) | 39 (3·6) | 23 (2·4) | 21 (2·8) |
| LMM | 139 (4·4) | 5 (1·3) | 42 (3·9) | 75 (7·9) | 17 (2·3) |
| Other | 46 (1·4) | 9 (2·3) | 1 (0·1) | 4 (0·4) | 32 (4·3) |
| Missing | 278 (8·7) | 36 (9·0) | 34 (3·1) | 191 (20·0) | 17 (2·3) |
| (n = 3125) | (n = 392) | (n = 1069) | (n = 926) | (n = 738) | |
| Breslow thickness (mm)* | 1·70 (1·10–3·00) | 1·90 (1·40–2·80) | 1·30 (0·88–2·40) | 2·00 (1·00–4·00) | 1·70 (1·20–2·70) |
| Clark level | |||||
| I–II | 271 (8·5) | 13 (3·3) | 60 (5·5) | 180 (18·9) | 18 (2·4) |
| III | 1230 (38·7) | 147 (36·9) | 400 (37·0) | 479 (50·3) | 204 (27·3) |
| IV | 1354 (42·6) | 188 (47·2) | 569 (52·6) | 219 (23·0) | 378 (50·6) |
| V | 140 (4·4) | 18 (4·5) | 31 (2·9) | 41 (4·3) | 50 (6·7) |
| Missing | 185 (5·8) | 32 (8·0) | 22 (2·0) | 34 (3·6) | 97 (13·0) |
| Ulceration | |||||
| No | 2264 (71·2) | 242 (60·8) | 874 (80·8) | 604 (63·4) | 544 (72·8) |
| Yes | 788 (24·8) | 92 (23·1) | 182 (16·8) | 339 (35·6) | 175 (23·4) |
| Missing | 128 (4·0) | 64 (16·1) | 26 (2·4) | 10 (1·0) | 28 (3·7) |
| Mitosis | |||||
| No | 39 (1·2) | 11 (2·8) | 0 (0) | 0 (0) | 28 (3·7) |
| Yes | 112 (3·5) | 59 (14·8) | 0 (0) | 0 (0) | 53 (7·1) |
| Missing | 3029 (95·3) | 328 (82·4) | 1082 (100) | 953 (100) | 666 (89·2) |
| (n = 3039) | (n = 397) | (n = 1072) | (n = 823) | (n = 747) | |
| Total no. of SNs* | 1 (1–2) | 2 (1–2) | 1 (1–2) | 1 (1–1) | 2 (2–3) |
| Multiple SN fields | |||||
| No | 2768 (87·0) | 337 (84·7) | 918 (84·8) | 953 (100) | 560 (75·0) |
| Yes | 412 (13·0) | 61 (15·3) | 164 (15·2) | 0 (0) | 187 (25·0) |
Values in parentheses are percentages unless indicated otherwise;
*
values are median (i.q.r.).
†
Based on 741 patients. EORTC, European Organization for Research and Treatment of Cancer; SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; SN, sentinel node.